Liu Y, Song B, Ran X, Jiang Q, Hu J, Vance Chiang S M
West China Hospital, Radiology, Chengdu, China.
West China Hospital, Endocrinology, Chengdu, China.
Exp Clin Endocrinol Diabetes. 2014 Feb;122(2):79-86. doi: 10.1055/s-0033-1363232. Epub 2014 Feb 19.
Islet replacement therapy, pancreatic islet transplantation, is considered as a potential option for curing T1DM. However, the significant loss of implanted islets after islet transplantation prevents it from becoming a mainstream treatment modality. Due to the lack of reliable noninvasive real-time imaging techniques to track the survival of the islets, it is impossible to discover the specific causes for the loss of implanted islets, not to mention taking interventions in the early stage. Current achievements in molecular imaging has provided with several promising techniques, including optical imaging, PET and MRI, for noninvasive visualization, quantification and functional evaluation of transplanted islets in experimental conditions. Optical imaging seems to be the most convenient and cost-efficient modality, but the limited penetration distance hinders its application in large animal and human studies. PET combined with target-specific tracers is characterized by high specificity and sensitivity for detection of islet grafts, but observation time is rather short (i.e., several hours). MRI stands out for its long-term visualization of transplanted islet grafts with the aid of contrast agents. However, quantification of islets remains a problem to be solved. A novel technique, microencapsulation, provides a new perspective in multimodal imaging by optimizing the strengths of several modalities together. Although the application of molecular imaging in clinical settings is still limited, significant success and valuable information is achieved in the basic and clinical trials. However, islet transplantation still remains an experimental procedure, with ongoing researches focusing on islets availability, appropriate sites for implantation, new methods using biomaterials (e.g. microencapsulation), immune modulation and more.
胰岛替代疗法,即胰岛移植,被认为是治愈1型糖尿病的一种潜在选择。然而,胰岛移植后植入胰岛的大量损失使其无法成为一种主流治疗方式。由于缺乏可靠的非侵入性实时成像技术来追踪胰岛的存活情况,无法发现植入胰岛损失的具体原因,更无法在早期进行干预。分子成像领域目前的成果提供了几种有前景的技术,包括光学成像、正电子发射断层扫描(PET)和磁共振成像(MRI),可在实验条件下对移植的胰岛进行非侵入性可视化、定量分析和功能评估。光学成像似乎是最便捷且成本效益最高的方式,但穿透距离有限阻碍了其在大型动物和人体研究中的应用。PET结合靶向特异性示踪剂对胰岛移植的检测具有高特异性和高灵敏度,但观察时间较短(即几个小时)。MRI借助造影剂对移植的胰岛移植物进行长期可视化方面表现突出。然而,胰岛的定量分析仍是一个有待解决的问题。一种新技术——微囊化,通过综合多种方式的优势,为多模态成像提供了新视角。尽管分子成像在临床环境中的应用仍然有限,但在基础和临床试验中已取得了显著成功并获得了有价值的信息。然而,胰岛移植仍然是一种实验性程序,目前正在进行的研究集中在胰岛的可获得性、合适的植入部位、使用生物材料的新方法(如微囊化)、免疫调节等方面。